HomepageMedicineFDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia Medicine FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia admin Posted on September 28, 2024 Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostWhy Do My Cats Farts Smell Like Eggs? Our Vet Explains Next PostChristian Louboutin Makes a Splash at Paris Fashion Week You Might Also Like Medicine Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy admin July 7, 2024 Medicine Solving the First Mile Problem: Q&A with Mark Melton admin April 29, 2024 Medicine CMS Signals Looming Sunshine Act Audits: How to Prepare admin March 2, 2024 Medicine Pharma Pulse 8/23/24: Drug Coverage Changes in Medicare Part D Plans, Law That Shielded Big Tech Now Being Used Against It & more admin August 26, 2024
Medicine Carvykti Demonstrates Clinically Meaningful Improvement in Patients with Relapsed or Lenalidomide-Refractory Multiple Myeloma After One Line of Prior Therapy admin July 7, 2024
Medicine Pharma Pulse 8/23/24: Drug Coverage Changes in Medicare Part D Plans, Law That Shielded Big Tech Now Being Used Against It & more admin August 26, 2024